Back to Search
Start Over
Observational, Multicenter Study on the Efficacy, Tolerability, and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis Older than 80 Years.
- Source :
-
Respiration . Jan2023, Vol. 102 Issue 1, p25-33. 9p. - Publication Year :
- 2023
-
Abstract
- Background: Idiopathic pulmonary fibrosis (IPF) primarily affects old patients. Old age is a predictor of mortality. Nintedanib, the only antifibrotic drug approved in Italy for patients aged >80 years, can slow the progression of IPF by reducing the rate of decline in forced vital capacity (FVC) and the risk of exacerbations. Objectives: The primary aim of the study was to compare the decline of FVC after 12 months of nintedanib in patients aged >80 years versus younger patients. Differences related to other functional data, safety, tolerability, hospitalizations, exacerbations, and mortality were evaluated. Methods: An observational, retrospective, multicenter study was carried out in Italy. Results: 159 (122 [76.7%] males) patients were recruited: 106 (66.7%) aged ≤80 years and 53 (33.3%) aged >80 years. FVC decline after 12 months of therapy was not significantly different (−45 mL [−170; 75] vs. −20 mL [−138; 110] mL; p: 0.51). No differences were found for other functional data. Diarrhea was the most frequent adverse event (AE). Rate and type of any AEs, permanent/temporary dose reduction, or drug discontinuation were not significantly different between patients aged ≤80 vs. >80 years. Furthermore, acute exacerbations, hospitalization, and mortality were not significantly different. Conclusions: Nintedanib is effective and safe in patients with IPF aged >80 years, and no significant differences were found when clinical outcomes were compared with those of younger patients. Thus, older age should not be a barrier for the early prescription of antifibrotic treatment in IPF patients. [ABSTRACT FROM AUTHOR]
- Subjects :
- *DRUG efficacy
*RESEARCH
*IDIOPATHIC pulmonary fibrosis
*DRUG tolerance
*SCIENTIFIC observation
*DIARRHEA
*ANTI-inflammatory agents
*FIBROSIS
*RETROSPECTIVE studies
*VITAL capacity (Respiration)
*TREATMENT effectiveness
*DESCRIPTIVE statistics
*DRUG side effects
*PATIENT safety
*DISEASE exacerbation
*EVALUATION
*OLD age
HOSPITAL care evaluation
Subjects
Details
- Language :
- English
- ISSN :
- 00257931
- Volume :
- 102
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Respiration
- Publication Type :
- Academic Journal
- Accession number :
- 161159963
- Full Text :
- https://doi.org/10.1159/000527308